What is Tirzepatide? The twins do different work.

Yes, a peptide. Yes, GLP-1. Also GIP.

Is tirzepatide a peptide or a GLP-1? The question mixes what a molecule is made of with what it does. Tirzepatide is a synthetic peptide—a chain of amino acids, the building pieces of proteins—and it activates both GIP and GLP-1 receptors. A receptor is the receiving part of a cell’s hormone-message system. The discovery account describes the dual action.

The chain contains 39 amino acids and is based on the natural GIP sequence. Tirzepatide itself is not a hormone the body makes. GIP and GLP-1 are gut-derived hormones involved in the insulin response to food; the medicine was engineered to imitate parts of their work.

“Twincretin,” or the plural “twincretins,” refers to that dual incretin idea. Incretins are the gut hormones that amplify insulin release after eating. I resist the shorthand “just a GLP-1”: it drops the feature that motivated the molecule’s development. The claim that two receptor targets make a better medicine still needs evidence. Human comparisons have to carry that argument.

Peptide describes the material. GIP/GLP-1 describes the receptor activity.

One chain, an unexpectedly uneven response

The original development work crossed several settings. Cells and mice supplied the early evidence; a Phase 1 programme in 142 human subjects then supported once-weekly administration and showed reductions in fasting glucose and weight versus placebo. A successful mouse experiment and an early human test answer different questions.

The more peculiar finding came in the 2020 receptor-signaling experiments. In cells and isolated islets, tirzepatide engaged the GIP receptor more fully than the GLP-1 receptor. At GLP-1, it favored cAMP signaling over beta-arrestin recruitment—different routes by which a receptor passes its message onward.

I had pictured an even division of labor. The experiments replaced that neat picture with something less symmetrical and more intriguing. To me, the uneven partnership is worth understanding, precisely because it spoils the slogan. These cell and islet findings do not prove which signaling difference caused the advantage in human trials.

“Imbalanced” describes the laboratory response without judging the medicine.

Built to linger

A fatty-diacid arm helps the peptide bind albumin, a protein in the blood. The structural account and early pharmacology describe how that modification gives tirzepatide a long stay in circulation. Its elimination half-life is approximately 5 days: after that interval, roughly half remains. The clinical programme used subcutaneous injection, meaning a shot beneath the skin.

This design choice has practical consequences beyond its chemical appeal. The gastric-emptying experiments found that tirzepatide transiently slows the stomach’s passage of food and that the effect attenuates with continued dosing. The effects entry considers why a slowed stomach matters beyond appetite.

Approval has an object

Tirzepatide first entered the U.S. FDA approval record in May 2022 for type 2 diabetes. The original prescribing information records that indication and the boxed thyroid C-cell tumor warning. The November 2023 chronic-weight-management approval covers adults with a BMI of 30 or more, or 27 or more with a weight-related condition. Moderate-to-severe obstructive sleep apnea in adults with obesity was approved subsequently, following the sleep-apnea trial programme.

The regulatory distinction matters: FDA-approved tirzepatide drugs exist, and compounded preparations are not FDA-approved. “Tirzepatide” identifies the molecule; the name alone cannot certify a preparation. Nor does an approved indication decide whether treatment fits a particular person. A licensed prescriber makes that decision.

I give the approval record considerable weight, while refusing to stretch it to every claim made around the molecule. The research comparisons show what the trials actually put to the test.